BURST: Biomarkers Underlying Rapid Symptom Treatment
This project will add biological, psychological, and social data collection as well as an additional treatment site (Tactical Mind Solutions) to an ongoing clinical trial studying daily oral, sub-hallucinogenic psilocybin over 28 days for generalized anxiety disorder. The study aims to better understand early treatment effects and identify objective signs of improvement. Data and biological samples collected under this award will be deidentified and housed in the ARPA-H EVIDENT Data and Biorepositories.